CONNECT WITH US
HealthTech

HealthTech

Sanofi has no plans for a 'major' overhaul as Dupixent's patent cliff looms

Endpoints News logo

Published on

Add as a preferred source on Google
Sanofi has no plans for a 'major' overhaul as Dupixent's patent cliff looms

Sanofi has no plans for a 'ma­jor' over­haul as Dupix­en­t's patent cliff looms

It’s been six months since Belén Gar­i­jo took over as the CEO for Sanofi, and the French drug­mak­er said Fri­day it is not plan­ning “ma­jor” …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

R&D chief Dean Li says Mer­ck out­flanked ri­vals with its sac-TMT can­cer pro­gram October 29, 2026

Gen­mab's stock ris­es on can­cer da­ta, while Io­vance, Co­herus tum­ble October 29, 2026

Af­ter Be Bio shut­down, its CEO heads to Or­bis; Enan­ta's long­time chief Jay Lu­ly to re­tire

Se­tara gets $90M to con­tin­ue rare dis­ease pipeline spun out of Jaz­z's Ac­tio deal

One-per­son biotechs and an 'age of mir­a­cles': An­throp­ic re­veals next leg of its bio­phar­ma vi­sion



Source link
Related Topics:HealthTech

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.